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S
o
o
J
D
J
T
a
F
b
c
d
a
A
R
A
K
C
B
C
A
1
a
a
m
o
c
w
b
a
h
h
0International Journal of Antimicrobial Agents 45 (2015) 420–423
Contents lists available at ScienceDirect
International  Journal  of  Antimicrobial  Agents
jo ur nal ho me  pag e: h t tp : / /www.e lsev ier .com/ locate / i jant imicag
hort  communication
-Lactam  antibiotics  and  vancomycin  inhibit  the  growth
f  planktonic  and  bioﬁlm  Candida  spp.:  An  additional  beneﬁt
f  antibiotic-lock  therapy?
osé  J.C.  Sidrima,  Carlos  E.C.  Teixeiraa,  Rossana  A.  Cordeiroa, Raimunda  S.N.  Brilhantea,∗,
ébora  S.C.M.  Castelo-Brancoa,  Silviane  P.  Bandeiraa, Lucas  P.  Alencara,
onathas  S.  Oliveiraa, André  J.  Monteirob, José  L.B.  Moreirac,
ereza  J.P.G.  Bandeiraa, Marcos  F.G.  Rochaa,d
Department of Pathology and Legal Medicine, College of Medicine, Post Graduate Program in Medical Microbiology, Specialized Medical Mycology Center,
ederal University of Ceará, Fortaleza, CE, Brazil
Department of Statistics and Applied Mathematics, Federal University of Ceará, Fortaleza, CE, Brazil
Department of Pathology and Legal Medicine, College of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil
College of Veterinary Medicine, Post Graduate Program in Veterinary Sciences, State University of Ceará, Fortaleza, CE, Brazil
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 26 May  2014
ccepted 1 December 2014
eywords:
andida spp.
ioﬁlms
atheter infection
a  b  s  t  r  a  c  t
The  aim of  this  study  was to  evaluate  the effects  of cefepime,  meropenem,  piperacillin/tazobactam  (TZP)
and vancomycin  on  strains  of  Candida  albicans  and Candida  tropicalis  in planktonic  and  bioﬁlm  forms.
Twenty  azole-derivative-resistant  strains  of  C. albicans  (n = 10)  and  C.  tropicalis  (n =  10)  were  tested.  The
susceptibility  of planktonic  Candida  spp.  to the  antibacterial  agents  was  investigated  by broth  microdi-
lution.  The  XTT  reduction  assay  was  performed  to evaluate  the viability  of  growing  and  mature  bioﬁlms
following  exposure  to these  drugs.  Minimum  inhibitory  concentrations  (MICs)  ranged  from  0.5 mg/mL
to  2  mg/mL  for  cefepime,  TZP  and  vancomycin  and  from  0.5 mg/mL  to 1  mg/mL  for  meropenem  andntibiotic-lock therapy the  drugs  also caused  statistically  signiﬁcant  reductions  in bioﬁlm  cellular  activity  both  in growing  and
mature  bioﬁlm.  Since  all of the  tested  drugs  are  commonly  used  in  patients  with  hospital-acquired  infec-
tions  and  in  those  with  catheter-related  infections  under  antibiotic-lock  therapy,  it may  be  possible  to
obtain  an  additional  beneﬁt  from  antibiotic-lock  therapy  with  these  drugs,  namely  the  control  of  Candida
bioﬁlm  formation.
©  2015  Elsevier  B.V.  and  the  International  Society  of  Chemotherapy.  All rights  reserved.. Introduction
Candida spp. are the fourth and third leading causes of hospital-
cquired bloodstream and urinary tract infections, respectively,
nd most of these infections are associated with implanted
edical devices such as central venous and bladder catheters
wing to bioﬁlm formation within these materials [1]. A relevant
haracteristic of Candida bioﬁlms is resistance to antifungal agents,
hich can be intrinsic or acquired by transfer of genetic material
etween bioﬁlm cells [2]. Bioﬁlm-associated Candida infections
re usually difﬁcult to diagnose, causing delayed therapy and
igh lethality rates in hospitalised patients worldwide [3], and
∗ Corresponding author. Tel.: +55 85 33668319; fax: +55 85 3295 1736.
E-mail address: brilhante@ufc.br (R.S.N. Brilhante).
ttp://dx.doi.org/10.1016/j.ijantimicag.2014.12.012
924-8579/© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rightsthe ability of Candida spp. to form drug-resistant bioﬁlms is an
important contributing factor to human diseases [1].
In systemic infections, bioﬁlms can also be polymicrobial,
formed by Candida spp. and bacteria [1]. Patients with con-
ﬁrmed or strongly suspected hospital-acquired infections primarily
receive antibacterial therapy, including cefepime, meropenem,
piperacillin/tazobactam (TZP) and vancomycin [4], which, on the
other hand, predisposes them to the occurrence of Candida infec-
tions because it decreases microbial competition within the host’s
microbiome [1,3]. It has already been shown that antibacte-
rial drugs can affect Candida bioﬁlm formation. Tigecycline, for
instance, is highly active against growing and mature bioﬁlms of
Candida albicans [5], whilst rifampicin can induce bioﬁlm forma-
tion by this Candida species [6]. Thus, this study aimed to evaluate
the effects of -lactams (cefepime, meropenem and TZP) and van-
comycin on strains of C. albicans and Candida tropicalis in planktonic
and bioﬁlm forms.
 reserved.
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. Materials and methods
.1. Fungal strains
Azole-derivative-resistant strains of Candida spp. from human
ases of candidaemia (four C. albicans and six C. tropicalis) and
ealthy animals (six C. albicans and four C. tropicalis) were included
n this study. The strains came from the culture collection of the
pecialized Medical Mycology Center of Federal University of Ceará
Fortaleza, Brazil) and were selected based on their antifungal resis-
ance [7]. The identity of the strains was conﬁrmed as previously
escribed [7].
.2. Antimicrobial agents and antifungal susceptibility of Candida
lanktonic cells
A stock solution of amphotericin B (AmB) (Sigma-Aldrich,
t Louis, MO)  at 1 mg/mL  was prepared according to Clini-
al and Laboratory Standards Institute (CLSI) guidelines [8] and
as used as a control. The antibacterial drugs cefepime (Nova-
arma, Anápolis, GO, Brazil), meropenem (AstraZeneca, Cotia, SP,
razil), TZP (Novafarma) and vancomycin (AstraZeneca) were
iluted with sterile distilled water as recommended by the
anufacturers. A stock solution of vancomycin was  prepared
ith distilled water at 50 mg/mL  as previously described [5]
nd, based on this research [5], the other antibacterial drugs
ere diluted to the same concentration. Serial two-fold dilu-
ions of each drug were prepared in RPMI 1640 medium with
-glutamine and without sodium bicarbonate (Sigma-Aldrich,
t Louis, MO), buffered to pH 7.0 with 0.165 M MOPS (3-
N-morpholino]propane sulfonic acid) (Sigma-Aldrich, St Louis,
O).
The susceptibility of Candida spp. to the antibacterial agents
as investigated by broth microdilution according to CLSI guide-
ines [8]. The ﬁnal inoculum was diluted with RPMI to reach a
oncentration of 0.5–2.5 × 103 cells/mL. AmB  was also tested as a
ontrol drug. To determine the susceptibility of planktonic cells, the
ested concentration ranges were 0.0039–4 mg/mL  for cefepime,
eropenem, TZP and vancomycin and 0.03125–16 g/mL for AmB.
ll isolates were tested in duplicate. For the antibacterial drugs,
he minimum inhibitory concentration (MIC) was deﬁned as the
owest drug concentration capable of inhibiting 50% of fungal
rowth [5] compared with the control well, whilst for AmB  the MIC
as deﬁned as the lowest drug concentration capable of inhibi-
ing 100% of planktonic fungal growth [8]. Escherichia coli ATCC
5922, Staphylococcus aureus ATCC 25923 and Candida parapsilo-
is ATCC 22019 were included as quality control strains for each
est [8].
.3. Bioﬁlm formation
For bioﬁlm testing, inocula were prepared as previously
escribed [9] with some modiﬁcations. Strains of C. albicans
n = 10) and C. tropicalis (n = 10) were grown in Sabouraud dextrose
roth (Himedia, Mumbai, India) at 30 ◦C for 24 h in a rotary
haker at 150 rpm. After this period, cells were collected by
entrifugation (3000 rpm, 10 min) and the pellet was washed
wice with phosphate-buffered saline (PBS). Suspensions were
djusted to 1 × 106 cells/mL in RPMI medium and then 100 L
liquots of inoculum were transferred to ﬂat wells of 96-well
olystyrene plates (TPP, Trasadingen, Switzerland). The plates
ere incubated at 37 ◦C for 48 h and the wells were washed three
imes with 0.05% Tween 20 (Sigma-Aldrich, São Paulo, SP, Brazil)
n Tris-buffered solution (Sigma-Aldrich, São Paulo, SP, Brazil)
o remove non-adherent cells. Bioﬁlm viability was monitoredtimicrobial Agents 45 (2015) 420–423 421
through the use of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT)
(Sigma-Aldrich, St Louis, MO)  as described previously [9].
2.4. Effect of antibacterial drugs on growing and mature Candida
bioﬁlms
The ability of the tested drugs to inhibit formation of C. albicans
and C. tropicalis bioﬁlms was  evaluated as described previously [9].
During the plate inoculation step, 100 L aliquots of the antibac-
terial solutions were added to each well. Each drug was tested at
ﬁve different concentrations (MIC/50, MIC/10, MIC, 10× MIC  and
50× MIC). Bioﬁlm formation was  then performed as previously
described. Following incubation at 37 ◦C for 48 h, the effect of the
antimicrobial drugs on growing bioﬁlms was evaluated based on
bioﬁlm cell activity using the XTT reduction assay with 75 L of
XTT salt solution (1 mg/mL  in PBS), 6 L of menadione solution
(1 mM in acetone) (Sigma-Aldrich, St Louis, MO) and 50 L of ster-
ile PBS, which were added to each well, followed by incubation
at 36 ◦C for 5 h. The metabolic activity of bioﬁlm cells was mea-
sured with a microplate reader (Epoch; Bio-Tek, Winooski, VT) at
492 nm.
The inhibitory activity of the tested drugs against mature
bioﬁlms of C. albicans and C. tropicalis was evaluated as previously
described [9]. The antibacterial drugs were tested at ﬁve different
concentrations (MIC/50, MIC/10, MIC, 10× MIC  and 50× MIC). For
this purpose, aliquots of 200 L of each drug were added to viable
48-h-old bioﬁlms grown in ﬂat wells of 96-well polystyrene plates,
followed by incubation at 35 ◦C for 48 h. After this period, inhibition
of bioﬁlm metabolic activity was  monitored by XTT reduction [9]
as described above.
All bioﬁlm experiments were performed in duplicate and were
repeated at three independent moments. Controls were grown in
medium without antimicrobials, and AmB  was used as the control
drug for bioﬁlm inhibition.
2.5. Statistical analysis
In order to verify differences in absorbance values to evaluate
the effects of antibacterial drugs on bioﬁlm cell activity, Student’s
t-test for paired samples was  used. For all of the analyses, a signiﬁ-
cance level lower than 5% indicated statistically signiﬁcant ﬁndings
(P < 0.05).
3. Results
The antibacterial MICs against the 20 tested Candida strains
ranged from 0.5 mg/mL  to 2 mg/mL  for cefepime and TZP and from
0.5 mg/mL  to 1 mg/mL  for meropenem. The MICs for vancomycin
ranged from 0.5 mg/mL  to 1 mg/mL  against C. albicans and from
0.5 mg/mL  to 2 mg/mL  against C. tropicalis. For AmB, the MICs
ranged from 0.5 g/mL to 2 g/mL against C. albicans and from
0.5 g/mL to 4 g/mL for C. tropicalis.
Regarding the effects of antibacterial drugs on growing Candida
spp. bioﬁlms, cefepime, TZP and vancomycin caused statisti-
cally signiﬁcant reductions in bioﬁlm cellular activity at MIC/10
(P < 0.001), MIC  (P < 0.0001), 10× MIC  (P < 0.0001) and 50× MIC
(P < 0.0001), whilst meropenem only caused signiﬁcant reductions
at the MIC  and higher concentrations (P < 0.05). AmB  signiﬁcantly
inhibited growing bioﬁlm cellular activity at all tested concentra-
tions (P < 0.01) (Fig. 1).
Regarding mature Candida bioﬁlms, cefepime, meropenem,
TZP and vancomycin caused statistically signiﬁcant reductions in
bioﬁlm cellular activity at MIC/10 (P < 0.05), MIC  (P < 0.01), 10×
MIC  (P < 0.0001) and 50× MIC  (P < 0.0001), but not at MIC/50
(Fig. 1) compared with the control growth. AmB  signiﬁcantly
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Fig. 1. Effect of different concentrations of cefepime, meropenem, piperacillin/tazobactam, vancomycin and amphotericin B (AMB) on the metabolic activity of growing and
mature bioﬁlms of Candida spp. analysed by the XTT reduction assay. The minimum inhibitory concentration (MIC) is that obtained against planktonic growth of Candida spp.
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oncentrations are presented in the following order top-down: 50× MIC, 10× MIC, 
nhibited mature bioﬁlm cellular activity at all tested concentra-
ions (P < 0.05) (Fig. 1).
. Discussion
The capacity of Candida to form bioﬁlms on abiotic and biotic
urfaces is an important virulence factor for the establishment of
ecurring candidiasis [10]. It is well known that the use of systemic
ntibiotics predisposes the proliferation of Candida spp., hence the
ccurrence of candidiasis [1,3]. However, little is known about the
ffects of antibiotics on growing and mature bioﬁlms of Candida
pp. within medical devices, which are continuously exposed to
ntibacterial drugs when patients are under treatment. This lack
f knowledge was a motivation to investigate the in vitro effects
f cefepime, meropenem, TZP and vancomycin, which are com-
only used against hospital-acquired infections [4], on Candida
ioﬁlms and, considering that these drugs predispose the occur-
ence of Candida infections, it was initially hypothesised that they
ould induce bioﬁlm formation or the maintenance of mature
ioﬁlms.
Initially, the antimicrobials were tested against azole-
erivative-resistant C. albicans and C. tropicalis strains and all
f them effectively inhibited the growth of planktonic Candida
pp., with MICs ranging from 0.5 mg/mL  to 2 mg/mL. Although all
ested antibacterial drugs were able to inhibit the in vitro growth of
lanktonic Candida, the MICs surpassed the desirable therapeutic
lood concentrations for all of these antibacterial drugs [11–14].
ence, they cannot be used to effectively treat Candida infections.
The mechanisms through which these antibacterial drugs
nhibited fungal growth remain unknown. Only a few studies
ave been performed tackling the effects of antibacterial drugs on
andida bioﬁlms and none of them have addressed possible mech-
nisms of action [5,6]. However, it can be suggested that these
rugs act through unspeciﬁc mechanisms, without speciﬁc target
olecules, since extremely high concentrations of the four tested
rugs were required to cause this growth inhibition. Thus, consid-
ring this new potential use of cefepime, meropenem, TZP and
ancomycin, it is necessary to design speciﬁc experimental proto-
ols to elucidate the mechanisms behind the observed antifungal
ffect.
On the other hand, the results demonstrate that antibacte-
ial concentrations as low as MIC/10 were capable of signiﬁcantly
educing the bioﬁlm cellular metabolic activity both of growing and
ature Candida bioﬁlms. The most interesting ﬁnding of this study
as that antibacterial concentrations lower than the MICs againstrowth at different antibacterial concentrations (P < 0.05). The tested antimicrobial
IC/10, MIC/50 and control.
planktonic cells were able to signiﬁcantly decrease the in vitro via-
bility of growing and mature Candida bioﬁlms.
Clinically, these ﬁndings may  be ground-breaking since all of
the tested antibacterial drugs (cefepime, meropenem, TZP and van-
comycin) are commonly used in patients with hospital-acquired
infections [4] and are also used in antibiotic-lock therapy [15]. This
technique involves the prolonged instillation of a solution contain-
ing extremely high concentrations of antimicrobial or antiseptic
agents, 100–1000-fold higher than those used systemically, within
an infected intravascular catheter as in an attempt to sterilise the
interior of the catheter and control bloodstream infections [5,15].
This kind of treatment appears to be a viable alternative in those
special cases in which the salvage of the catheter is desirable,
although removing the device is the treatment of choice for per-
sistent or complicated bacteraemia or fungaemia related to its use
[15].
It is important to emphasise that the use of systemic broad-
spectrum antibiotics is an important risk factor for developing
candidaemia and that bioﬁlms play a major role in main-
taining bloodstream Candida infections [10]. Therefore, consid-
ering the low minimum antibacterial concentrations (MIC/10;
50–200 g/mL) required to signiﬁcantly decrease the viability
of Candida bioﬁlm cells, we believe that the use of cefepime,
meropenem, TZP and vancomycin in the antimicrobial-lock solu-
tion might not only aid the patient in the management of bacterial
infection associated with indwelling catheters, but also control the
formation of Candida bioﬁlms within these medical devices during
antibacterial therapy. However, more studies will be necessary to
establish the effects of this therapy on Candida bioﬁlms inside the
patient during treatment.
5. Conclusion
The antibacterial drugs cefepime, meropenem, TZP and van-
comycin are able to decrease the in vitro viability of growing and
mature Candida bioﬁlms. These results may  bring the perspec-
tive of obtaining an additional beneﬁt with antibiotic-lock therapy,
namely the control of fungal bioﬁlms when using these drugs in
hospitalised patients.
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